Circulating Dickkopf-1 and sclerostin in patients with Paget’s disease of bone
- 221 Downloads
Paget disease of bone is a chronic metabolic bone disorder characterized by increased bone resorption and new bone formation. The aim of this study is defining the role of inhibitors of canonical Wnt/b-catenin signaling pathway in patients with Paget disease of bone. Scarce and contrasting results have been reported in literature. We studied 40 patients (15 females and 25 males) with radiological and scintigraphic evidence of Paget disease of bone and 40 healthy subjects matched by age and sex. N-propeptide of type I collagen, C-terminal telopeptide of type I collagen, sclerostin, and Dickkopf-related protein 1 (DKK1) were evaluated by blood samples in our laboratory. As expected, mean serum levels of bone turnover markers (N-propeptide of type I collagen and C-terminal telopeptide of type I collagen) were significantly higher in the Paget disease of bone group compared with the control group. No difference was observed between groups in Dickkopf-1 and sclerostin. Dickkopf-1 and sclerostin were never correlated with each other or with bone turnover markers. Sclerostin was positively correlated with age. In conclusion, our results suggest that the regulators of the Wnt-β catenin pathway are not altered in patients with Paget disease of bone. The positive correlation we found between sclerostin and age in Paget disease of bone patients indicates that in comparative studies, sclerostin serum levels must be adjusted for age.
KeywordsBone turnover DKK1 Paget disease of bone Sclerostin Wnt pathway
We thank Caterina Fraccarollo and Cristina Bosco for the ELISA assays.
Compliance with ethical standards
Conflict of interest
Dr. Idolazzi reports personal fees from Abbvie, personal fees from Novartis, personal fees from Eli Lilly, and personal fees from UCB, outside the submitted work.
Dr. Fassio has nothing to disclose.
Dr. Tripi has nothing to disclose.
Dr. Braga has nothing to disclose.
Dr. Viapiana reports personal fees from Abiogen, personal fees from Amgen, and personal fees from Merck Sharp & Dohme Corp, outside the submitted work.
Dr. Adami has nothing to disclose.
Prof. Rossini reports personal fees from Abiogen, personal fees from Amgen, personal fees from Merck Sharp & Dohme Corp, and personal fees from Eli Lilly, outside the submitted work.
Prof. Gatti reports personal fees from Abiogen, personal fees from Amgen, personal fees from Merck Sharp & Dohme Corp, and personal fees from Eli Lilly, outside the submitted work.
- 22.Polyzos SA, Anastasilakis AD, Litsas I, Sapranidis M, Efstathiadou Z, Kita M et al (2010) Dual-energy X-ray absorptiometry and quantitative ultrasound in patients with Paget’s disease of bone before and after treatment with zoledronic acid: association with serum bone markers and Dickkopf-1. J Clin Densitom 13(2):190–196CrossRefPubMedGoogle Scholar
- 25.Ross AC, Taylor CL, Yaktine AL, Del Valle HB (eds) (2011) Dietary Reference Intakes for Calcium and Vitamin D. Institute of Medicine (US) Committee to Review Dietary Reference Intakes for Vitamin D and Calcium. National Academies Press (US), Washington (DC)Google Scholar